ArticleScientific reports2025
Profiling short-term longitudinal severity progression and associated genes in COVID-19 patients using EHR and single-cell analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Here we propose CovSF, a deep learning model designed to track and forecast short-term severity progression of COVID-19 patients using longitudinal clinical records. The motivation stems from the need for timely medical resource allocation, improved treatment decisions during pandemics, and the understanding of severity progression related immunology. The COVID-19 Severity Forecasting model, CovSF, utilizes 15 clinical features to profile the severity levels of hospital admitted patients and also forecast their severity levels of up to three days ahead. CovSF was trained on a large COVID-19 cohort (n=4,509), achieving an AUROC of 0.92 with 0.85 and 0.89 sensitivity and specificity on an external validation dataset (n=443). The type of oxygen therapy administered was utilized as the target predictive label, which is often used as the severity index. This approach enables the inclusion of a more comprehensive dataset encompassing patients across the full spectrum of severity, rather than restricting the analysis to more narrowly defined outcomes such as ICU admission or mortality. We focused on profiling deteriorating and recovering health conditions, which were validated using patient matched single-cell transcriptomes. Especially, we showed that the immunology significantly differed between the samples during deterioration and recovery, whose severity levels were the same, and thus presenting the importance of longitudinal analysis. We believe that the framework of CovSF can be extended to other respiratory infectious diseases to alleviate the strain of allocating hospital resources, especially in pandemics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.